Swiss pharmaceutical giant Novartis is facing a defining moment in its corporate history as its heavy reliance on bolt-on acquisitions…
Read More
UK Life Sciences Sector Faces Funding Crisis Despite Government Prioritisation
The United Kingdom’s ambitious plans to foster growth within its vital life sciences sector are facing significant headwinds, with industry…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
Europe Faces a Decade-High Surge in Sexually Transmitted Infections, Highlighting Urgent Need for Enhanced Prevention and Treatment Strategies
New data released by Europe’s leading infectious disease agency reveals a concerning decade-high surge in bacterial sexually transmitted infections (STIs),…
Read More
Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…
Read More
Eli Lilly Faces Regulatory Scrutiny Over Foundayo’s Long-Term Safety Profile
Eli Lilly has swiftly responded to concerns raised by the US Food and Drug Administration (FDA) regarding the long-term safety…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
TrumpRx.gov: A Federal Portal Faces Scrutiny Amidst Concerns Over Direct-to-Consumer Drug Sales and Patient Safety.
As of early February, the federal portal TrumpRx.gov remains in a nascent state, displaying only a stylized Oval Office portrait…
Read More
